Literature DB >> 22542539

Prolonged survival and milder impairment of motor function in the SOD1 ALS mouse model devoid of fibroblast growth factor 2.

Nadine Thau1, Julia Jungnickel, Sarah Knippenberg, Andreas Ratzka, Reinhard Dengler, Susanne Petri, Claudia Grothe.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by selective motoneuron loss in brain and spinal cord. Mutations in the superoxide dismutase (SOD) 1 gene account for 10-20% of familial ALS patients. The ALS-mouse model over-expressing a mutant human SOD1 (G93A) gene closely mimics human ALS disease. The cause for the selective death of motoneurons is still unclear, but among several pathomechanisms discussed, loss of neurotrophic factors is one possibility. Basic fibroblast growth factor 2 (FGF-2) plays a prominent role in the motor system. In order to evaluate a role of FGF-2 in ALS pathogenesis, double mouse mutants transgenic for the human SOD1 mutation and lacking the endogenous FGF-2 gene were generated. Both heterozygous and homozygous FGF-2 deficient mutant SOD1 mice showed a significant delay in disease onset and less impaired motor performance in comparison to mutant SOD1 mice with normal FGF-2 levels. Survival of the double mouse mutants was significantly prolonged for two weeks. Motoneuron numbers were significantly higher in the double mutants and astrocytosis was diminished at disease endstage. While one would initially have expected that FGF-2 deficiency deteriorates the phenotype of mutant SOD1 animals, our results revealed a protective effect of FGF-2 reduction. In search of the underlying mechanisms, we could show up-regulation of other neurotrophic factors with proven protective effects in the ALS mouse model, ciliary neurotrophic factor (CNTF) and glial derived neurotrophic factor (GDNF) in muscle and spinal cord tissue of double mutant animals.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542539     DOI: 10.1016/j.nbd.2012.04.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  11 in total

1.  Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice.

Authors:  Hui Sun; Sarah Knippenberg; Nadine Thau; Daniela Ragancokova; Sonja Körner; Dongya Huang; Reinhard Dengler; Klaus Döhler; Susanne Petri
Journal:  Cell Mol Neurobiol       Date:  2012-12-28       Impact factor: 5.046

Review 2.  A nuclear odyssey: fibroblast growth factor-2 (FGF-2) as a regulator of nuclear homeostasis in the nervous system.

Authors:  Benjamin Förthmann; Claudia Grothe; Peter Claus
Journal:  Cell Mol Life Sci       Date:  2015-01-01       Impact factor: 9.261

3.  Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Savina Apolloni; Paola Fabbrizio; Chiara Parisi; Susanna Amadio; Cinzia Volonté
Journal:  Mol Neurobiol       Date:  2014-12-09       Impact factor: 5.590

Review 4.  Fibroblast Growth Factor Signalling in the Diseased Nervous System.

Authors:  Lars Klimaschewski; Peter Claus
Journal:  Mol Neurobiol       Date:  2021-04-15       Impact factor: 5.590

5.  SOD mRNA and MDA expression in rectus femoris muscle of rats with different eccentric exercise programs and time points.

Authors:  Heng Zhao; Jiani Liu; Shinong Pan; Yingwei Sun; Qi Li; Fei Li; Li Ma; Qiyong Guo
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

Review 6.  What Can We Learn from FGF-2 Isoform-Specific Mouse Mutants? Differential Insights into FGF-2 Physiology In Vivo.

Authors:  Friederike Freiin von Hövel; Ekaterini Kefalakes; Claudia Grothe
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 5.923

Review 7.  Physical Exercise-Induced Myokines in Neurodegenerative Diseases.

Authors:  Banseok Lee; Myeongcheol Shin; Youngjae Park; So-Yoon Won; Kyoung Sang Cho
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

8.  CSF cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy.

Authors:  Takahiro Furukawa; Naoko Matsui; Koji Fujita; Hiroyuki Nodera; Fumitaka Shimizu; Katsuichi Miyamoto; Yukitoshi Takahashi; Takashi Kanda; Susumu Kusunoki; Yuishin Izumi; Ryuji Kaji
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-08-06

9.  Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in Amyotrophic Lateral Sclerosis (ALS)--in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia.

Authors:  Hui Sun; Karelle Bénardais; Nancy Stanslowsky; Nadine Thau-Habermann; Niko Hensel; Dongya Huang; Peter Claus; Reinhard Dengler; Martin Stangel; Susanne Petri
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

10.  Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis.

Authors:  Savina Apolloni; Susanna Amadio; Chiara Parisi; Alessandra Matteucci; Rosa L Potenza; Monica Armida; Patrizia Popoli; Nadia D'Ambrosi; Cinzia Volonté
Journal:  Dis Model Mech       Date:  2014-07-18       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.